医院管理

基于压疮治疗方式的不同对 DRG 入组的特征与应用的研究

A study on the characteristics and application of DRG admission based on different treatment methods for pressure ulcers

:1599-1604
 
       目的   通过对压疮不同治疗方式的分析,探讨疾病诊断相关分组(DRG)组合的特征,提高核心疾病诊断相关组(ADRG)的入组率和提升相对权重值,从而提升医疗服务效率和水平。方法   使用医院DRGs分析评价系统以及EXCEL软件筛选出2023—2024年广州市第一人民医院主要诊断压疮疾病病例,分析ADRG组合的特征。结果   根据压疮疾病不同治疗方式,主要诊断为压疮(L89)的176病例进入相对的外科治疗组和内科治疗组,ADRG组分别为JD1组合、JJ1组合、JV1组合。JJ1组合治疗方案以创面封闭式负压引流为主;JD1组合的外科治疗方式均是以皮肤和皮下坏死组织的切除清创术+创面封闭式负压引流术(VSD)的手术治疗方案。JD13组、JD15组比JJ13组、JJ15组,相对权重分别高2.35和1.48。26例患者的住院时间均超过60 d,导致进入了QY组合。结论   利用好DRGs工具能有效地提高压疮的入组率,结合精细化的首页质量管理,提升DRGs的组合权重值及医疗服务效率和水平。
       Objective  To analyze  different treatment methods for  pressure  ulcers and explore the characteristics of Diagnosis-Related Groups(DRGs)to improve the admission rate of Adjacent DRGs(ADRGs)and enhance the  relative weight value,thereby improving the efficiency and level of medical services.Methods  Using the DRGs management system and EXCEL software,cases of pressure ulcer disease from Class A tertiary hospital in Guangzhou from 2023 to 2024 were selected,with pressure ulcers as the primary diagnosis,and analyzed the characteristics of ADRG combinations.Results  Based on different treatment methods for pressure ulcers,176 cases primarily diagnosed with pressure ulcers(L89)were categorized into  relative surgical and medical treatment groups,with ADRG groups being JD1,JJ1,and JV1 combinations.The JJ1 group’s treatment plan primarily focused on closed wound negative pressure drainage,the surgical treatment method for JD1 group involved skin and subcutaneous necrotic tissue excision and debridement surgery combined with closed wound negative pressure drainage(VSD).The  relative weights of JD13 and JD15 groups were 2.35 and 1.48,higher than those of JJ13 and JJ15 groups.Twenty-six cases had an average hospital stay exceeding 60 days,leading to their categorization into the QY group.Conclusions  Utilizing the DRG tool effectively improves the admission rate for pressure ulcer diseases.By combining it with refined quality management on the first page of medical records,the combination weight value of DRGs and the efficiency and level of medical services can be enhanced.
医院管理

广州某三甲医院脑梗死住院费用及其影响因素分析

Analysis of hospitalization expenses and influencing factors of cerebral infarction in a tertiary general hospital in Guangzhou

:950-957
 
目的 分析广州某三甲医院脑梗死患者住院费用的变化以及影响因素,为有效减轻患者疾病经济负担提供参考依据。方法 提取广州某三甲医院2015—2022年出院诊断ICD-10前三位编码为I63的病案首页数据,并采用IBM SPSS 20.0软件对费用结构进行描述性统计分析,以多重线性回归分析患者住院费用的影响因素。结果 2015—2022年脑梗死患者的平均住院费用年均增长率为2.86%;费用结构以药品费为主,占比逐年下降,至2022年占比为27.74%,技术劳务性费用占比逐年增加,至2022年占比为47.41%;住院费用主要受医院感染情况、住院天数以及支付方式等因素影响(F=990.10,P<0.001)。结论 脑梗死患者的住院费用结构显著优化,但患者的疾病经济负担仍然较重,且费用受多种因素的综合影响。建议通过提高医疗质量与服务效能,并严格落实临床路径管理,减少不必要的检查以及耗材使用,以期最大程度地减轻患者的负担。
Objective To analyze the structural changes and influencing factors of the hospitalization expenses for patients with cerebral infarction in a tertiary general hospital in Guangzhou,and provide a scientific basis for reducing economic burden of the patients.Methods The front page data of medical records with the main diagnosis of I63 were collected in the sample hospital.Descriptive statistics analysis of hospitalization expenses structure and multiple linear regression analysis of the influencing factors were carried out by SPSS 20.0.Results The annual growth rate of average hospitalization expenses of cerebral infarction patients from 2015 to 2022 in the sample hospital was 2.86% per year.The highest proportion of hospitalization expenses was medicine fee,the proportion of which declined year by year with a minimum 27.74% in 2022.The proportion of technical labor costs accelerated year by year with a maximum 47.41% in 2022.This study revealed the main factors influencing hospitalization expenses were hospital internal infection or not,length of stay,payment method and so on(F=990.10,P<0.001).Conclusions The structure of hospitalization expenses for cerebral infarction patients was significantly optimized,but the economic burden of patients was still heavy affected by a combination of factors.In order to minimize the burden of patients,hospitals should improve medical quality and service efficiency and implement clinical pathway management strictly,to reduce unnecessary inspections and consumables.
论著

化疗联合NKG2A抑制剂抗头颈部鳞状细胞癌作用的研究

Effect of chemotherapy combined with NKG2A inhibitor on head and neck squamous cell carcinoma

:860-868
 
目的 研究靶向NKG2A抑制剂抗头颈部鳞状细胞癌(HNSCC)的作用。方法 应用GEO和TCGA数据库分析NKG2A及其配体HLA-E单细胞表达情况、与患者预后以及免疫微环境的相关性。构建HNSCC皮下抑制瘤模型,流式细胞技术检测化学治疗(化疗)对免疫检测点NKG2A表达的影响。动物实验验证NKG2A抑制剂以及NKG2A抑制剂联合多西他赛化疗的抗肿瘤作用。结果 NKG2A(KLRC1)主要表达在NK细胞,少量表达在T淋巴细胞。HNSCC肿瘤高表达NKG2A/HLA-E(P<0.01),与患者不良预后密切相关;肿瘤微环境中NKG2A/HLA-E与多个免疫细胞浸润以及免疫检测点表达密切相关(P<0.01)。动物实验显示化疗能上调T、B淋巴细胞表达免疫检查点NKG2A的表达水平(P<0.01);化疗的基础上联合NKG2A抑制剂能更有效地介导抗肿瘤作用(P=0.013)。结论 化疗基础上联合NKG2A抑制剂能更有效地介导抗肿瘤作用,为探索HNSCC临床新策略提供实验和理论基础。
Objective To investigate the anti-tumor effects of NKG2A inhibitor on head and neck squamous cell carcinoma(HNSCC).Methods The single-cell expression of NKG2A ,its ligand HLA-E and their correlations with patient prognosis and immune microenvironment were analyzed in GEO and TCGA databases.The subcutaneous tumor model of HNSCC was constructed,and the effects of chemotherapy on the expression of NKG2A on T and B lymphocytes were detected by flow cytometry.Animal experiments were used to confirmed the anti-tumor effects of NKG2A inhibitor and NKG2A inhibitors combined with docetaxel.Results NKG2A(KLRC1)was mainly expressed in NK cells,and a small amount was expressed in T lymphocytes.The high expression of NKG2A/HLA-E in HNSCC tumors(P<0.01)were closely related to poor prognosis.NKG2A/HLA-E in tumor microenvironment were closely related to the infiltration of multiple immune cells and the expression of immune checkpoints(P<0.01).Animal experiments showed that chemotherapy could up-regulate the expression of NKG2A in T and B lymphocytes(P<0.01).Chemotherapy in combination with NKG2A inhibitor could mediate more effective antitumor effects in HNSCC(P=0.013).Conclusions Combined with NKG2A inhibitor on the basis of chemotherapy can mediate more effective anti-tumor effects,and this study may provide experimental and theoretical basis for exploring new clinical strategies of HNSCC.
专家述评

运动捕捉技术在步态分析中的研究进展

Research progress of motion capture technology in gait analysis

:826-835
 
运动捕捉技术已经广泛应用于步态分析、运动康复、动作对比、技战术分析、生物运动力学分析、损伤防护、运动装备设计研发等领域,实现了人机交互的全新体验。而步行是人类运动中最基础的动作,在生物力学研究上对异常步态进行分析能够有效改善患者治疗和康复的效果。本文总结了运动捕捉技术在各种异常步态分析中的应用,并对其优缺点进行了总结与展望。检索PubMed、Embase、EBSCO、Web of Science、中国知网,收集2018年1月至2023年12月公开发表的有关有标记运动捕捉及无标记运动捕捉在异常步态的相关研究,进行系统综述。最终纳入了22篇英文文献,这些文献主要集中在神经科学、生物医学工程和临床医学等领域,特别是在步态分析、运动捕捉技术、神经病理学和康复医学等方面的应用。这些研究为我们理解和改善各种神经系统疾病,如帕金森病、多发性硬化症和脑卒中以及骨关节炎等疾病的步态提供了宝贵的见解。利用运动捕捉来进行异常步态分析能有效地给患者提供准确的康复治疗,将结果用于临床诊断、康复规划或研究目的。异常步态分析在评估肌肉骨骼状况、神经系统疾病或干预措施的有效性方面具有重要价值。
Motion capture technology has been widely used in the fields of gait analysis,sports rehabilitation,action comparison,technical and tactical analysis,biomotor mechanics analysis,injury protection,sports equipment design and development,etc.,which realizes a brand-new experience of human-computer interaction.While walking is the most basic action in human movement,the analysis of abnormal gait on biomechanical research can effectively improve the effect of patient treatment and rehabilitation.This paper summarizes the application of motion capture technology in the analysis of various abnormal gaits,and summarizes and prospects its advantages and disadvantages.PubMed,Embase,EBSCO,Web of Science and China Knowledge Network were searched to collect related studies,openly published from January 2018 to December 2023,about labeled motion capture and unlabeled motion capture in abnormal gait for systematic review.Twenty-two English-language papers were finally included,which focused on the fields of neuroscience,biomedical engineering and clinical medicine,especially in the applications of gait analysis,motion capture technology,neuropathology and rehabilitation medicine.These studies provide valuable insights into understanding and improving gait in various neurological disorders such as Parkinson’s disease,multiple sclerosis and stroke and osteoarthritis.The use of motion capture for abnormal gait analysis can be effective in providing accurate rehabilitation to patients,using the results for clinical diagnosis,rehabilitation planning,or research purposes.Abnormal gait analysis is valuable in assessing musculoskeletal conditions,neurological disorders,or the effectiveness of interventions.
专家述评

创新引领数智镇痛医疗规范化高质量发展

Guiding the development of digital analgesia technology standards with high standards of excellence and quality

:820-825
 
1994年中国引进患者自控镇痛(PCA),经过国人改造升级如今已取得了令人瞩目的成绩:2007年《术后患者自控镇痛临床研究与推广应用》获教育部科学技术进步奖二等奖和中华医学科技奖三等奖;2011年具有中国自主专利产权和创新数字医疗的智能化患者自控镇痛(Ai-PCA)诞生,2019年《智能化术后患者自控镇痛管理关键技术及其临床应用》获得中国抗癌协会科技奖二等奖;2023年《中国分娩镇痛规范及推广应用》获得华夏医学科技奖二等奖。笔者撰写述评,提出努力推进Ai-PCA高水平高质量发展的措施,呼吁国内学者重视引领数智镇痛医疗规范化,于2024年在《中华疼痛学杂志》刊出由余守章教授牵头制定的《患者自控镇痛临床应用规范专家共识》,助力中国数智镇痛医疗技术向智慧化前行,为人民群众切实享受到舒适镇痛提供更优质的服务。
Since the introduction of Patient-Controlled Analgesia(PCA)in China in 1994,the domain has witnessed its substantial advancements.The project,Clinical Research and Promotion of Postoperative Patient-Controlled Analgesia,achieved the Ministry of Education’s Second Prize for Scientific and Technological Progress and the Chinese Medical Association’s Third Prize in 2007.The innovation continued in 2011 with the development of an intelligent PCA system(Ai-PCA)endowed with Chinese independent patent rights and innovative digital medical technology.In 2019,the Key Technologies and Clinical Application of Intelligent Postoperative Patient-Controlled Analgesia Management was honored with the second-class Science and Technology Award by the Chinese Anti-Cancer Association.Furthering this trend.In 2023,the Standards and Promotion of Labor Analgesia in China secured the second-class prize in Medical Science and Technology from Huaxia Medical Science and Technology.This commentary suggest strategies for the qualitative enhancement of Ai-PCA and urge domestic scholars to spearhead the standardization of Ai-PCA.Expert Consensus on Clinical Application Standards for Patient-Controlled Analgesia leaded and edited by Pro.She has published,in 2024,which fervently supports the advancement of China’s Ai-PCA technology towards a more intelligent future,to provide the public with higher quality and more comfortable pain management services.
论著

ALBI联合NLR预测肝硬化合并食管胃底静脉曲张破裂出血的作用

The role of ALBI combined with NLR in predicting liver cirrhosis complicated with esophageal and gastric varices bleeding

:387-392
 
目的 探讨白蛋白-胆红素(ALBI)联合中性粒细胞与淋巴细胞比值(NLR)预测肝硬化合并食管胃底静脉曲张破裂出血(EGVB)的临床价值。方法 回顾性分析2021年1月—2022年12月肇庆市第一人民医院消化内科收治的80例肝硬化合并EGVB患者的临床资料,通过电话及门诊、再入院对其进行为期1年的随访,根据随访结果,将其分为2组,即存活组(n=69)与死亡组(n=11),分析导致患者死亡的危险因素,并评估ALBI联合NLR预测肝硬化合并EGVB患者死亡的临床价值。结果 死亡组的年龄60岁以上、腹水和肝性脑病者占比,总胆红素(TBiL)、NLR、凝血酶原时间(PT)、谷丙转氨酶(ALT)水平及ALBI评分均高于存活组(均P<0.05),而血红蛋白(HGB)、白蛋白(ALB)及血钠水平均低于存活组(均P<0.05);Logtisic回归分析显示,年龄60岁以上、腹水、肝性脑病和TBiL、NLR水平升高及ALBI分级为3级是肝硬化合并EGVB患者死亡的危险因素(均P<0.05);ALBI联合NLR预测肝硬化合并EGVB患者预后的准确率及灵敏度高于单一诊断,漏诊率低于单一诊断(P<0.05)。结论 肝硬化合并EGVB患者可见ALBI评分及NLR水平升高,而以上两种指标是患者死亡的危险因素,将其联合检测可评估患者预后,预测其死亡风险。
Objective To investigate the clinical value of albumin-bilirubin(ALBI)combined with neutrophil lymphocyte ratio(NLR)in predicting liver cirrhosis complicated with esophageal and gastric varices bleeding(EGVB).Methods The clinical data of 80 patients with liver cirrhosis complicated with EGVB admitted to the Department of Gastroenterology of the First People's Hospital of Zhaoqing from January 2021 to December 2022 were retrospectively analyzed.They were followed up for one year by telephone,outpatient service and readmission.According to the follow-up results,they were divided into the survival group(n=69)and the death group(n=11).The risk factors leading to the death of patients were analyzed and evaluated.Results The proportion of age over 60,ascites and hepatic encephalopathy,the levels of TBiL,NLR,PT,ALT and ALBI in the death group were higher(P<0.05),while the levels of HGB,ALB and blood sodium were lower(P<0.05).Logistics analysis showed that age over 60,ascites,hepatic encephalopathy,NLR and ALBI grade 3 were independent risk factors for the death(P<0.05).The accuracy and sensitivity of ALBI combined with NLR in predicting their prognosis were significantly higher than that of single diagnosis,and the missed diagnosis rate was lower(P<0.05).Conclusions ALBI scores and NLR levels significantly increase in patients with liver cirrhosis complicated with EGVB,and the above two indexes are risk factors for the death,and the combination of them can evaluate the prognosis of patients and predict the death risk.
论著

MR引导的海马保护用于小细胞肺癌全脑放疗

Hippocampal avoidant whole brain radiotherapy guided by MR of small cell lung cancer

:330-337
 
目的 研究核磁共振(MR)引导的海马保护技术应用于小细胞肺癌全脑放射治疗(放疗)的效果。方法 对确定行全脑放疗的30例小细胞肺癌脑转移患者,行常规放疗CT定位后以定位体位行全头颅MR平扫,将计算机断层扫描(CT)和MR的T1加权像在Monaco 5.1计划系统上进行精准融合,勾画全脑放疗及海马区域,在海马区域三维方向上分别外扩5、15 mm作为海马与计划靶区之间的剂量跌落,每一例患者在Monaco 5.1计划系统上按照不保护海马组织以及外扩5、15 mm进行保护设计3个容积旋转调强技术(VMAT)放疗计划,观察海马组织的平均及最大放疗剂量。结果 增加保护海马组织之后,3个放疗计划的D100均≥95%,每例的3个放疗计划间D100比较差异无统计学意义(P>0.05);设置外扩5、15 mm的剂量跌落区后,左、右海马的平均剂量、最大剂量均明显降低,而且3个放疗计划的海马平均剂量、最大剂量之间对比差异有统计学意义。结论 小细胞肺癌脑转移患者进行全脑放疗时,利用MR引导的海马保护技术并设置外扩15 mm的剂量跌落区,能够显著降低海马的剂量,达到保护目的。
Objective To explore the application of MR guided hippocampal avoidant whole brain radiotherapy(WBRT)for small cell lung cancer(SCLC).Methods Thirty SCLC patients with brain metastases who underwent WBRT were enrdled.After routine CT localization was performed,and a head MR was performed in a the same position.T1 weighted images of MR and CT images were accurately fused on the Monaco 5.1 planning system.The entire brain tissue and hippocampus region were delineated. The dose drop areas between the hippocampus and the planned target area were expanded 5mm and 15mm in the three-dimensional direction of the hippocampus,respectively.Three volumetric modulated arc therapy(VMAT)radiotherapy plans were designed for each patient on the Monaco 5.1 planning system based on whether the hippocampal tissue was avoid.The average and maximum doses of hippocampal tissue were observed.Results After the avoidance of hippocampal tissue,the D100 of the three radiotherapy plans reached ≥95%,and there was no significant difference in D100 between the three radiotherapy plans in each case.After setting dose drop areas of 5mm and 15mm for external expansion,the average and maximum doses of the left and right hippocampus were significantly reduced,and there was a significant difference in the comparison between the average and maximum doses in the hippocampus of the three radiotherapy plans.Conclusions MR guided hippocampal avoidant technology and the setting of a 15 mm dose drop area can significantly reduce the dose to the hippocampus in patients with SCLC undergo whole brain radiotherapy.
综述

lncRNA linc-UBC1在恶性肿瘤发生发展中的作用研究进展

Research progress of long non-coding RNA linc-UBC1 in the development of malignant tumors

:323-329
 
长链非编码RNA(lncRNA)是一类长度大于200个核苷酸转录本,通过调控DNA、RNA及蛋白质的表达和功能,参与肿瘤发生、发展并发挥重要作用的RNA,近年来lncRNA成为恶性肿瘤早期诊断和预后标志物研究新的关注方向。Linc-UBC1作为一种新发现的lncRNA,在多种恶性肿瘤如肺癌、胃癌、结直肠癌、宫颈癌、卵巢癌、食管鳞癌等中异常高表达,可通过作为竞争性RNA(ceRNA)、参与信号通路等促进肿瘤细胞的增殖、迁移、侵袭、细胞周期进展、细胞凋亡和上皮间充质转化(EMT)等过程;高表达的linc-UBC1能够增加恶性肿瘤的耐药性,其表达水平与肿瘤分期、淋巴结转移和原发肿瘤远处转移呈正相关;linc-UBC1有望成为许多恶性肿瘤的新型的生物标志物、预后预测因子和治疗靶点,但其具体的调控机制仍处于研究的早期阶段,有待进一步深入研究。文章就目前linc-UBC1在恶性肿瘤发生和发展中的作用研究进展进行综述。
Long non-coding RNA(lncRNA)is a class of transcripts with a length of more than 200 nucleotides.It is involved in the occurrence and development of tumors and plays an important role by regulating the expression and function of DNA,RNA and protein.In recent years,lncRNA has become a new research direction for early diagnosis and prognosis of malignant tumors.As a newly discovered lncRNA,linc-UBC1 is abnormally highly expressed in a variety of malignant tumors such as lung cancer,gastric cancer,colorectal cancer,cervical cancer,ovarian cancer,and esophageal squamous cell carcinoma.It can promote the proliferation,migration,invasion,cell cycle progression,cell apoptosis and EMT of tumor cells by acting as a competing endogenous RNA(ceRNA)and participating in signaling pathways.High expression of linc-UBC1 can increase the drug resistance of malignant tumors,and its expression level is positively correlated with tumor stage,lymph node metastasis and distant metastasis of primary tumors.linc-UBC1 is expected to become a new biomarker,prognostic predictor and therapeutic target for many malignant tumors,while its specific regulatory mechanism is still in the early stage of research and needs further in-depth study.This article reviews the current research progress of linc-UBC1 in the occurrence and development of malignant tumors.
论著

CT增强延迟扫描技术在非小细胞肺癌术前诊断中的应用价值

The application value of CT enhanced delayed scanning in preoperative diagnosis of non-small cell lung cancer

:547-552
 
目的 探讨CT增强延迟扫描技术在非小细胞肺癌术前诊断中的应用价值。方法 对2021年5月—2024年5月商丘市第一人民医院收治的82例非小细胞肺癌手术治疗患者进行回顾性分析,将其分为观察组,另选取82例肺部良性肿瘤患者作为对照组,收集其术前CT增强延迟扫描结果,以术后病理诊断结果为金标准,分析CT增强延迟扫描技术在非小细胞肺癌术前诊断中的应用价值。并对比不同临床病理特征非小细胞肺癌患者CT增强延迟扫描的CT增强值,采用Spearman相关性分析法分析CT增强值与非小细胞肺癌病理特征的关系。结果 CT增强延迟扫描显示观察组患者分叶征(12.50% vs 53.57%)、内部空泡征数量(6.25% vs 39.29%)低于对照组(χ2=26.560、24.680,P<0.05),观察组患者边缘毛刺(56.25% vs 17.86%)、胸部凹陷征(59.38% vs 14.29%)、高于对照组(χ2=43.330、64.600,P<0.05);82例非小细胞肺癌通过CT增强延迟扫描共确诊79例,CT增强延迟扫描诊断对非小细胞肺癌的准确率为96.34%(79/82),与病理诊断结果100.00%对比差异无统计学意义(χ2=3.060,P=0.080);82例非小细胞肺癌平均CT增强值为(39.14±7.31),不同性别、年龄、肿瘤最大直径、淋巴结浸润情况患者CT增强值对比差异无统计学意义(P>0.05),不同病理类型[腺癌(43.75±7.15)vs 鳞癌(34.74±6.12)]、细胞分化程度[中、低分化(45.71±7.21)vs 高分化(32.81±5.11)]、临床分期[Ⅰ期(31.03±2.12)vs Ⅱ期(36.61±3.13)vs Ⅲa期(46.32±6.83)]患者、淋巴结转移[是(42.75±4.21)vs 否(35.77±8.13)]CT增强值对比差异有统计学意义(t/F=5.243、8.804、84.828、4.378,P<0.05);Spearman相关分析结果显示:病理类型、细胞分化程度、临床分期、淋巴结转移与非小细胞肺癌患者CT增强值呈正相关(r=0.431,P=0.021;r=0.511,P=0.009;r=0.586,P=0.005;r=0.579,P=0.008,P<0.05)。结论 CT增强延迟扫描技术对非小细胞肺癌术前确诊具有重要价值,其诊断准确率与病理诊断并无显著差异,且可通过CT增强延迟扫描技术确定患者CT增强值,从而为非小细胞肺癌患者术后病理特征判断提供参考。
Objective To explore the application value of CT enhanced delayed scanning in preoperative diagnosis of non-small cell lung cancer(NSCLC).Methods A retrospective analysis was conducted on 82 patients with NSCLC who underwent surgical treatment in a hospital from May 2021 to May 2024.They were included into an observation group and another 82 patients with benign lung tumors were included in the control group.The preoperative CT enhanced delayed scanning results were collected,and the postoperative pathological diagnosis was used as the “gold standard” to analyze the application value of CT enhanced delayed scanning in the preoperative diagnosis of NSCLC.And the CT enhancement values of delayed CT scans in NSCLC patients with different clinical and pathological features were compared,and Spearman correlation analysis was used to analyze the relationship between CT enhancement values and pathological features of NSCLC.Results CT enhanced delayed scanning showed that the number of lobular(12.50% vs 53.57%)and internal vacuolar signs(6.25% vs 39.29%)in the observation group was significantly lower than that in the control group(χ2=26.560,24.680,P<0.05),while the edge spicules(56.25% vs 17.86%)and chest depression signs(59.38% vs 14.29%)in the observation group were significantly higher than that in the control group(χ2=43.330,64.600,P<0.05).A total of 79 cases of 82 NSCLC were diagnosed by CT-enhanced delayed scan,and the accuracy of CT-enhanced delayed scan diagnosis for NSCLC was 96.34%(79/82),with no significant difference from the pathological diagnosis result of 100.00%(χ2=3.060,P=0.080).The average CT enhancement value of 82 NSCLC cases was(39.14±7.31).There was no significant difference in CT enhancement values among patients of different genders,ages,maximum tumor diameter,and lymph node infiltration(P>0.05).Patients with different pathological types [adenocarcinoma(43.75±7.15)vs squamous cell carcinoma(34.74±6.12)],degree of cell differentiation [moderate,and low differentiation(45.7±7.21)vs high differentiation(32.81±5.11)],clinical stage [I(31.03±2.12)vs II(36.61±3.13)vs IIIa(46.32±6.83)] and lymph node metastasis [yes(42.75±4.21),vs no(35.77±8.13)] CT enhancement had significant difference(t/F=5.243,8.804,84.828,4.378,P<0.05).The Spearman correlation analysis results showed that pathological type,degree of cell differentiation,clinical stage,lymph node metastasis were positively correlated with CT enhancement values in NSCLC patients(r=0.431,P=0.021;r=0.511,P=0.009;r=0.586,P=0.005;r=0.579,P=0.008).Conclusions CT enhanced delayed scanning has important value in preoperative diagnosis of NSCLC.Its diagnostic accuracy is not significantly different from pathological diagnosis,and the CT enhanced value of patients can be determined through CT enhanced delayed scanning,providing reference for postoperative pathological feature judgment of NSCLC patients.
论著

不同针具在治疗腰椎间盘突出症的有效性与安全性的系统评估和网状Meta分析

A systematic assessment and network meta-analysis of the efficacy and safety of different needles in the treatment of lumbar disc herniation

:469-485
 
目的 评价现有关于干预组仅涉及不同针具针刺或联合常规针刺治疗腰椎间盘突出症系统评价的方法学质量,以比较不同针具针刺治疗腰椎间盘突出症的治疗效果。方法 通过CNKI(中国知网)、万方数据库、VIP(维普)、PubMed、Web of Science等数据库以及其他相关电子资源,对诊断、治疗腰椎间盘突出症的多种针灸技术进行全面的研究。使用AMSTAR2软件,对所有参与的系统性评估结果进行地分析,并根据不同的检测结果,确定文献筛选标准。通过Revman5.4和Cochrance风险偏倚工具,以及Stata16.0的网格Meta分析,挑选了3 381个满足纳入排除要求的随机对照试验。结果 以Stata 16.0统计软件制作排序图可知,杵针+电针的临床有效率SUCRA=81.6%排名第一;目测类比评分显示,银质针SUCRA(用于评估疗效的指标)=95%,排名第一。结论 根据现有的研究证据,杵针+电针以及银质针优于其他9种干预措施,但确切的结果仍需要大量的随机对照试验来证明。
Objective To evaluate the methodological quality of the existing systematic evaluation of the intervention group involving only different needle sets of acupuncture or combined with conventional acupuncture in the treatment of lumbar disc herniation,in order to compare the therapeutic effect of different needle sets of acupuncture in the treatment of lumbar disc herniation.Methods Through CNKI,Wanfang database,VIP,PubMed,web of science and other databases as well as other relevant resources,a variety of acupuncture techniques for the diagnosis and treatment of lumbar disc herniation were comprehensively studied.Through the use of AMSTAR2 software,all participating systematic evaluation results were effectively analyzed,and according to different test results,which literature meets the requirements were determined.Through revman5.4,Cochrane risk bias tool,and grid meta-analysis of stata16.0,3 381 RCTs meeting the inclusion and exclusion requirements were selected.Results According to the ranking chart made by stata16.0 statistical software,the clinical effective rate of pestle needle + electroacupuncture ranked first with sucra=81.6%.According to the visual analogy score,the silver needle sucra=95%,ranking first.Conclusions According to the existing research evidence,pestle needle + electroacupuncture and silver needle are better than the other nine interventions,but the exact results still need a large number of randomized controlled trials to prove.
出版者信息








《广州医药》公众号